ZUMA-7 Axi-Cel Superiority Calls for Treatment Paradigm Shift in R/R LBLC

Article

The analysis of data from ZUMA-7 demonstrated significant efficacy for axi-cel over second-line standard treatment.

Data from ZUMA-7, a multicenter phase 3 trial, demonstrated statistically significant and clinically relevant improvements in event-free survival (EFS) and response rates in patients with relapsed/refractory large B-cell lymphoma (LBLC) treated with axicabtageneciloleucel (axi-cel) versus second-line standard of care (SOC) chemoimmunotherapy.

The findings, presented at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (2022 Tandem Meetings), held in Salt Lake City, Utah, and virtually April 23-26, 2022, suggest that axi-cel should be considered second-line SOC for r/r LBLC.

The data presented included findings from 359 patients who were randomly assigned to receive either axi-cel (n=180) or SOC (n=179). Participants, of whom 74% had primary refractory disease, had a median age of 59. The primary end point was event-free survival, and secondary end points included objective response rate and overall survival.

Treatment with axi-cel met the primary end point, with EFS significantly longer at 24.9 months in the axi-cel group compared with SOC (8.3 months vs 2 months, P <.0001). In addition, EFS Kaplan-Meier estimates were 41% and 16%, respectively, and objective response rates (ORR) and complete response (CR) rates were higher in the axi-cel group compared with SOC (ORR: 83% vs 50%, odds ratio: 5.31 [95% CI, 3.1-8.9; P <.0001]; CR: 65% vs 32%). Median overall survival, evaluated as an interim analysis, was not reached for axi-cel vs 35.1 months for SOC (HR 0.730; P=.027). Notably 56% of patients in the SOC arm received crossover treatment with axi-cel off-protocol.

Progression-free survival (PFS) was also superior in the axi-cel group, with median PFS 14.7 months in the axi-cel cohort compared with 3.7 months in the SOC cohort.

“This intent to treat PFS curve compares favorably to the modified intent to treat PFS curve from ZUMA-1, suggesting that efficacy of axi-cel in a second line setting may be superior to efficacy seen in a third or later line,” primary investigator Frederick Locke, MD, of Moffitt Cancer Center, said during the data presentation.

In terms of safety, 91% (axi-cel) and 83% (SOC) of patients reported Grade 3 or higher treatment-emergent adverse events (TEAEs), with 1 and 2 patient treatment-related deaths occurring in each group, respectively. Grade 3 or higher cytokine release syndrome and neurologic events ccurred in 6% and 21% of the axi-cel group, with no grade 5 events recorded.

Notably, of the 180 participants randomized to axi-cel, 170 (94%) ultimately received definitive therapy compared with 36% of the SOC arm.

Overall, axi-cel demonstrated a more than 4-fold greater median EFS, 2.5-fold greater 2-year EFS, and 2-fold greater CR rate compared with SOC.

REFERENCE
Locke FL, Miklos DB, Perales MA, et al. Primary Analysis of Zuma‑7: A Phase 3 Randomized Trial of AxicabtageneCiloleucel (Axi-Cel) Versus Standard‑of‑Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Presented at: Presented at: the 2022 Transplantation & Cellular Therapy Meetings; Salt Lake City, UT; April 23-26, 2022.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.